Astex Pharmaceuticals, Inc·4

Jul 3, 5:49 PM ET

LACK WALTER J 4

4 · Astex Pharmaceuticals, Inc · Filed Jul 3, 2012

Insider Transaction Report

Form 4
Period: 2012-06-29
Transactions
  • Exercise/Conversion

    Common Stock

    2012-06-29$2.14/sh+15,000$32,100395,000 total
  • Exercise/Conversion

    Director Stock Option (Right to buy)

    2012-06-2910,0000 total
    Exercise: $2.14Exp: 2020-06-10Common Stock (10,000 underlying)
  • Exercise/Conversion

    Common Stock

    2012-06-29$2.14/sh+10,000$21,400415,000 total
  • Exercise/Conversion

    Common Stock

    2012-06-29$2.14/sh+10,000$21,400405,000 total
  • Exercise/Conversion

    Director Stock Option (Right to buy)

    2012-06-2915,0000 total
    Exercise: $2.14Exp: 2020-06-10Common Stock (15,000 underlying)
  • Exercise/Conversion

    Director Stock Option (Right to buy)

    2012-06-2910,0000 total
    Exercise: $2.14Exp: 2020-06-10Common Stock (10,000 underlying)
Footnotes (2)
  • [F1]3,750 shares of the 15,000 share option grant became exercisable on the June 10, 2010 grant date and on each three month anniversary thereafter.
  • [F2]2,500 shares of the 10,000 share option grant became exercisable on the June 10, 2010 grant date and on each three month anniversary therafter.

Documents

1 file
  • 4
    edgar.xmlPrimary

    FORM 4 -